Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
APG-1387 plus chemotherapy in advanced pancreatic cancer
NCT04643405Phase 2Terminated
- Sponsor
- Ascentage Pharma
- Start
- Mar 2021
- Primary completion
- Jun 2024
- Modality
- Molecular Glues
- Countries
- 1
01
Overview
A Phase 2 trial of dasminapant in pancreatic adenocarcinoma (PDAC), sponsored by Ascentage Pharma. Started Mar 2021; status: terminated.
02
Drugs
dasminapant
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT04643405.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04643405.